{"pmid":32503140,"title":"Human T leukaemia Type 1 and COVID-19.","text":["Human T leukaemia Type 1 and COVID-19.","In the absence of clinical data on Human T leukaemia Type 1 and COVID-19 infection, we are providing guidance to clinicians who look after people living with HTLV-1.","Pathogens","Araujo, Abelardo","Martin, Fabiola","32503140"],"abstract":["In the absence of clinical data on Human T leukaemia Type 1 and COVID-19 infection, we are providing guidance to clinicians who look after people living with HTLV-1."],"journal":"Pathogens","authors":["Araujo, Abelardo","Martin, Fabiola"],"date":"2020-06-07T11:00:00Z","year":2020,"_id":"32503140","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.3390/pathogens9060438","weight":0,"_version_":1668892488228667392,"score":9.490897,"similar":[{"pmid":32428243,"title":"Acute promyelocytic leukaemia lying under the mask of COVID-19-a diagnostic and therapeutic conundrum.","text":["Acute promyelocytic leukaemia lying under the mask of COVID-19-a diagnostic and therapeutic conundrum.","The diagnosis and management of acute promyelocytic leukaemia (APML) in the context COVID-19 poses a challenge for clinicians. We present a case illustrating this due to the masking of the typical laboratory pattern of APML coagulopathy and the potential heightened risks of thrombosis and differentiation syndrome (DS) when the two conditions are combined.","Br J Haematol","Farmer, Isabel","Okikiolu, Jumoke","Steel, Matthew","Wanniarachchi, Chandima","Littlewood, Shona","Gupta, Sunil","Thanigaikumar, Muragaiyan","Oram, S Helen","Moonim, Mufaddal","Kulasekararaj, Austin G","Yeghen, Tullie","32428243"],"abstract":["The diagnosis and management of acute promyelocytic leukaemia (APML) in the context COVID-19 poses a challenge for clinicians. We present a case illustrating this due to the masking of the typical laboratory pattern of APML coagulopathy and the potential heightened risks of thrombosis and differentiation syndrome (DS) when the two conditions are combined."],"journal":"Br J Haematol","authors":["Farmer, Isabel","Okikiolu, Jumoke","Steel, Matthew","Wanniarachchi, Chandima","Littlewood, Shona","Gupta, Sunil","Thanigaikumar, Muragaiyan","Oram, S Helen","Moonim, Mufaddal","Kulasekararaj, Austin G","Yeghen, Tullie"],"date":"2020-05-20T11:00:00Z","year":2020,"_id":"32428243","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1111/bjh.16864","topics":["Diagnosis"],"weight":1,"_version_":1667252837826953217,"score":95.18025},{"pmid":32415723,"title":"Australian and New Zealand consensus statement on the management of lymphoma, chronic lymphocytic leukaemia and myeloma during the COVID-19 pandemic.","text":["Australian and New Zealand consensus statement on the management of lymphoma, chronic lymphocytic leukaemia and myeloma during the COVID-19 pandemic.","The COVID-19 pandemic poses a unique challenge to the care of patients with haematological malignancies. Viral pneumonia is known to cause disproportionately severe disease in patients with cancer, and patients with lymphoma, myeloma and chronic lymphocytic leukaemia are likely to be at particular risk of severe disease related to COVID-19. This statement has been developed by consensus among authors from Australia and New Zealand. We aim to provide supportive guidance to clinicians making individual patient decisions during the COVID-19 pandemic, in particular during periods that access to healthcare resources may be limited. General recommendations include those to minimise patient exposure to COVID-19, including the use of telehealth, avoidance of non-essential visits and minimisation of time spent by patients in infusion suites and other clinical areas. This statement also provides recommendations where appropriate in assessing indications for therapy, reducing therapy-associated immunosuppression and reducing healthcare utilisation in patients with specific haematological malignancies during the COVID-19 pandemic. Specific decisions regarding therapy of haematological malignancies will need to be individualised, based on disease risk, risks of immunosuppression, rates of community transmission of COVID-19 and available local healthcare resources.","Intern Med J","Di Ciaccio, Pietro","McCaughan, Georgia","Trotman, Judith","Ho, Phoebe Joy","Cheah, Chan Y","Gangatharan, Shane","Wight, Joel","Ku, Matthew","Quach, Hang","Gasiorowski, Robin","Polizzotto, Mark N","Prince, Henry Miles","Mulligan, Stephen","Tam, Constantine S","Gregory, Gareth","Hapgood, Greg","Spencer, Andrew","Dickinson, Michael","Latimer, Maya","Johnston, Anna","Armytage, Tasman","Lee, Cindy","Cochrane, Tara","Berkhahn, Leanne","Weinkove, Robert","Doocey, Richard","Harrison, Simon J","Webber, Nicholas","Lee, Hui-Peng","Chapman, Scott","Campbell, Belinda A","Gibbs, Simon D J","Hamad, Nada","32415723"],"abstract":["The COVID-19 pandemic poses a unique challenge to the care of patients with haematological malignancies. Viral pneumonia is known to cause disproportionately severe disease in patients with cancer, and patients with lymphoma, myeloma and chronic lymphocytic leukaemia are likely to be at particular risk of severe disease related to COVID-19. This statement has been developed by consensus among authors from Australia and New Zealand. We aim to provide supportive guidance to clinicians making individual patient decisions during the COVID-19 pandemic, in particular during periods that access to healthcare resources may be limited. General recommendations include those to minimise patient exposure to COVID-19, including the use of telehealth, avoidance of non-essential visits and minimisation of time spent by patients in infusion suites and other clinical areas. This statement also provides recommendations where appropriate in assessing indications for therapy, reducing therapy-associated immunosuppression and reducing healthcare utilisation in patients with specific haematological malignancies during the COVID-19 pandemic. Specific decisions regarding therapy of haematological malignancies will need to be individualised, based on disease risk, risks of immunosuppression, rates of community transmission of COVID-19 and available local healthcare resources."],"journal":"Intern Med J","authors":["Di Ciaccio, Pietro","McCaughan, Georgia","Trotman, Judith","Ho, Phoebe Joy","Cheah, Chan Y","Gangatharan, Shane","Wight, Joel","Ku, Matthew","Quach, Hang","Gasiorowski, Robin","Polizzotto, Mark N","Prince, Henry Miles","Mulligan, Stephen","Tam, Constantine S","Gregory, Gareth","Hapgood, Greg","Spencer, Andrew","Dickinson, Michael","Latimer, Maya","Johnston, Anna","Armytage, Tasman","Lee, Cindy","Cochrane, Tara","Berkhahn, Leanne","Weinkove, Robert","Doocey, Richard","Harrison, Simon J","Webber, Nicholas","Lee, Hui-Peng","Chapman, Scott","Campbell, Belinda A","Gibbs, Simon D J","Hamad, Nada"],"date":"2020-05-17T11:00:00Z","year":2020,"_id":"32415723","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1111/imj.14859","keywords":["covid-19","chronic lymphocytic leukaemia","lymphoma","myeloma"],"locations":["Australia","New Zealand","Australian","New Zealand","lymphoma"],"countries":["Australia","New Zealand"],"countries_codes":["AUS|Australia","NZL|New Zealand"],"topics":["Prevention"],"weight":1,"_version_":1666991242696720384,"score":85.407486},{"pmid":32368790,"title":"Ph+ Acute Lymphoblastic Leukaemia in Italy During the Covid-19 Pandemic. A Campus ALL Study.","text":["Ph+ Acute Lymphoblastic Leukaemia in Italy During the Covid-19 Pandemic. A Campus ALL Study.","The recent spread of the Covid-19 infection has raised important questions within the haematology community on how best to manage and treat patients with haematological malignancies, particularly acute leukaemias. Italy has witnessed a dramatic raise in infections and death rates, that has hit in particular certain areas of the most populated Northern regions of the country (Lombardia, Veneto, Piemonte, Emilia Romagna). Within the nationwide Campus ALL programme in the last week of March we sent a questionnaire addressing different issues related to the management of adult ALL patients during the Covid-19 pandemic to 40 haematology centres located on the entire territory.","Br J Haematol","Foa, Robin","Bonifacio, Massimiliano","Chiaretti, Sabina","Curti, Antonio","Candoni, Anna","Fava, Carmen","Ciccone, Maria","Pizzolo, Giovanni","Ferrara, Felicetto","32368790"],"abstract":["The recent spread of the Covid-19 infection has raised important questions within the haematology community on how best to manage and treat patients with haematological malignancies, particularly acute leukaemias. Italy has witnessed a dramatic raise in infections and death rates, that has hit in particular certain areas of the most populated Northern regions of the country (Lombardia, Veneto, Piemonte, Emilia Romagna). Within the nationwide Campus ALL programme in the last week of March we sent a questionnaire addressing different issues related to the management of adult ALL patients during the Covid-19 pandemic to 40 haematology centres located on the entire territory."],"journal":"Br J Haematol","authors":["Foa, Robin","Bonifacio, Massimiliano","Chiaretti, Sabina","Curti, Antonio","Candoni, Anna","Fava, Carmen","Ciccone, Maria","Pizzolo, Giovanni","Ferrara, Felicetto"],"date":"2020-05-06T11:00:00Z","year":2020,"_id":"32368790","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1111/bjh.16758","locations":["Italy","Northern","Lombardia","Veneto","Piemonte","Italy"],"countries":["Italy"],"countries_codes":["ITA|Italy"],"topics":["Prevention"],"weight":1,"_version_":1666138496223412225,"score":77.84969},{"pmid":32424293,"title":"COVID-19 in persons with chronic myeloid leukaemia.","text":["COVID-19 in persons with chronic myeloid leukaemia.","We studied by questionnaire 530 subjects with chronic myeloid leukaemia (CML) in Hubei Province during the recent SARS-CoV-2 epidemic. Five developed confirmed (N = 4) or probable COVID-19 (N = 1). Prevalence of COVID-19 in our subjects, 0.9% (95% Confidence Interval, 0.1, 1.8%) was ninefold higher than 0.1% (0, 0.12%) reported in normals but lower than 10% (6, 17%) reported in hospitalised persons with other haematological cancers or normal health-care providers, 7% (4, 12%). Co-variates associated with an increased risk of developing COVID-19 amongst persons with CML were exposure to someone infected with SARS-CoV-2 (P = 0.037), no complete haematologic response (P = 0.003) and co-morbidity(ies) (P = 0.024). There was also an increased risk of developing COVID-19 in subjects in advanced phase CML (P = 0.004) even when they achieved a complete cytogenetic response or major molecular response at the time of exposure to SARS-CoV-2. 1 of 21 subjects receiving 3rd generation tyrosine kinase-inhibitor (TKI) developed COVID-19 versus 3 of 346 subjects receiving imatinib versus 0 of 162 subjects receiving 2nd generation TKIs (P = 0.096). Other co-variates such as age and TKI-therapy duration were not significantly associated with an increased risk of developing COVID-19. Persons with these risk factors may benefit from increased surveillance of SARS-CoV-2 infection and possible protective isolation.","Leukemia","Li, Weiming","Wang, Danyu","Guo, Jingming","Yuan, Guolin","Yang, Zhuangzhi","Gale, Robert Peter","You, Yong","Chen, Zhichao","Chen, Shiming","Wan, Chucheng","Zhu, Xiaojian","Chang, Wei","Sheng, Lingshuang","Cheng, Hui","Zhang, Youshan","Li, Qing","Qin, Jun","Meng, Li","Jiang, Qian","32424293"],"abstract":["We studied by questionnaire 530 subjects with chronic myeloid leukaemia (CML) in Hubei Province during the recent SARS-CoV-2 epidemic. Five developed confirmed (N = 4) or probable COVID-19 (N = 1). Prevalence of COVID-19 in our subjects, 0.9% (95% Confidence Interval, 0.1, 1.8%) was ninefold higher than 0.1% (0, 0.12%) reported in normals but lower than 10% (6, 17%) reported in hospitalised persons with other haematological cancers or normal health-care providers, 7% (4, 12%). Co-variates associated with an increased risk of developing COVID-19 amongst persons with CML were exposure to someone infected with SARS-CoV-2 (P = 0.037), no complete haematologic response (P = 0.003) and co-morbidity(ies) (P = 0.024). There was also an increased risk of developing COVID-19 in subjects in advanced phase CML (P = 0.004) even when they achieved a complete cytogenetic response or major molecular response at the time of exposure to SARS-CoV-2. 1 of 21 subjects receiving 3rd generation tyrosine kinase-inhibitor (TKI) developed COVID-19 versus 3 of 346 subjects receiving imatinib versus 0 of 162 subjects receiving 2nd generation TKIs (P = 0.096). Other co-variates such as age and TKI-therapy duration were not significantly associated with an increased risk of developing COVID-19. Persons with these risk factors may benefit from increased surveillance of SARS-CoV-2 infection and possible protective isolation."],"journal":"Leukemia","authors":["Li, Weiming","Wang, Danyu","Guo, Jingming","Yuan, Guolin","Yang, Zhuangzhi","Gale, Robert Peter","You, Yong","Chen, Zhichao","Chen, Shiming","Wan, Chucheng","Zhu, Xiaojian","Chang, Wei","Sheng, Lingshuang","Cheng, Hui","Zhang, Youshan","Li, Qing","Qin, Jun","Meng, Li","Jiang, Qian"],"date":"2020-05-20T11:00:00Z","year":2020,"_id":"32424293","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1038/s41375-020-0853-6","locations":["Hubei"],"countries":["China"],"countries_codes":["CHN|China"],"e_drugs":["Imatinib Mesylate"],"topics":["Prevention"],"weight":1,"_version_":1667352728691539968,"score":77.215004},{"pmid":32369614,"title":"Concomitant hemorrhagic syndrome and recurrent extensive arterial thrombosis in a patient with COVID-19 and acute promyelocytic leukemia.","text":["Concomitant hemorrhagic syndrome and recurrent extensive arterial thrombosis in a patient with COVID-19 and acute promyelocytic leukemia.","Acute promyelocytic leukaemia and COVID-19 are two conditions associated with severe coagulopathy. We present here the multiple haemostasis abnormalities observed in a patient with concomitant acute promyelocytic leukaemia and COVID-19. The clinical consequences were dramatic and led to the death of the patient. A 62-year old woman was admitted on April 13, 2020 for unexplained asthenia, dyspnoea, and uncontrolled epistaxis. Clinical examination revealed pallor, left periorbital ecchymosis due to a recent fall, intrabuccal haemorrhagic bullae, persistent epistaxis, and mild splenomegaly. Oxygen saturation was 96%. Chest computed tomography (CT) was consistent with moderate COVID-19 pneumonia (9 points on a 0-25 scale)(Pan, et al 2020). The qRT-PCR of a nasopharyngeal swab was positive for SARS-CoV2.","Br J Haematol","Baldacini, Mathieu","Pop, Raoul","Sattler, Laurent","Mauvieux, Laurent","Bilger, Karin","Gantzer, Justine","Schneider, Francis","Beaujeux, Remy","Simand, Celestine","Herbrecht, Raoul","32369614"],"abstract":["Acute promyelocytic leukaemia and COVID-19 are two conditions associated with severe coagulopathy. We present here the multiple haemostasis abnormalities observed in a patient with concomitant acute promyelocytic leukaemia and COVID-19. The clinical consequences were dramatic and led to the death of the patient. A 62-year old woman was admitted on April 13, 2020 for unexplained asthenia, dyspnoea, and uncontrolled epistaxis. Clinical examination revealed pallor, left periorbital ecchymosis due to a recent fall, intrabuccal haemorrhagic bullae, persistent epistaxis, and mild splenomegaly. Oxygen saturation was 96%. Chest computed tomography (CT) was consistent with moderate COVID-19 pneumonia (9 points on a 0-25 scale)(Pan, et al 2020). The qRT-PCR of a nasopharyngeal swab was positive for SARS-CoV2."],"journal":"Br J Haematol","authors":["Baldacini, Mathieu","Pop, Raoul","Sattler, Laurent","Mauvieux, Laurent","Bilger, Karin","Gantzer, Justine","Schneider, Francis","Beaujeux, Remy","Simand, Celestine","Herbrecht, Raoul"],"date":"2020-05-06T11:00:00Z","year":2020,"_id":"32369614","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1111/bjh.16768","topics":["Case Report"],"weight":1,"_version_":1666138496221315073,"score":52.868828}]}